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Introduction {#onco13121-sec-0003}
============

The detection of lymph node metastasis affects the management of patients with primary breast cancer significantly in terms of staging, treatment, and prognosis [1](#onco13121-bib-0001){ref-type="ref"}. Formerly, axillary lymph node dissection (ALND) in clinically positive axilla was the state‐of the‐art procedure to determine staging and achieve regional control in patients with breast cancer. However, its associated comorbidities (lymphedema, restriction of arm and shoulder movement, numbness of upper arm skin, etc.) have spurred efforts in the last decades to provide a highly selective approach for the assessment of lymph node involvement [2](#onco13121-bib-0002){ref-type="ref"}, [3](#onco13121-bib-0003){ref-type="ref"}, [4](#onco13121-bib-0004){ref-type="ref"}. Sentinel lymph node biopsy is currently the most accurate method for axillary staging [5](#onco13121-bib-0005){ref-type="ref"}. Since 2005, it has been recommended by the American Society of Clinical Oncology as an initial alternative to upfront ALND in patients with early‐stage breast cancer, ensuring that only women with positive findings in the sentinel nodes would undergo complete dissection [6](#onco13121-bib-0006){ref-type="ref"}. Recently, data from the American College of Surgeons Oncology Group Z0011 trial suggested that even patients with a stage T1 or T2 tumor and one or two positive sentinel lymph nodes with no extracapsular extension can be spared ALND [1](#onco13121-bib-0001){ref-type="ref"}, [7](#onco13121-bib-0007){ref-type="ref"}.

The radiologist has an important role in the preoperative imaging of the axilla and sampling of abnormal lymph nodes. The goal is to determine and detect the presence of metastatic disease in nonpalpable axillary lymph nodes (low or high tumor burden) with a positive predictive value that is high enough to initially select patients for upfront ALND. Imaging characteristics that are indicative of axillary lymph node metastatic involvement can be seen with mammography (MG), computed tomography (CT), and magnetic resonance imaging (MRI). Nevertheless, ultrasonography (US) is the method of choice for axillary lymph nodes assessment and for performing image‐guided lymph node interventions.

In this review, we aim to provide a comprehensive overview of the available imaging modalities for lymph node assessment in patients diagnosed with primary breast cancer. First, we introduce the basic anatomy of the axilla, as this serves as an important knowledge base to understand the metastatic pathways of spread, and then we briefly summarize the N‐staging guidelines from the latest edition of the TNM staging guidelines for Breast Cancer from the American Joint Commission on Cancer (AJCC) [8](#onco13121-bib-0008){ref-type="ref"}. We then focus on providing details on the interpretation of suspicious nodal features from the available imaging modalities.

In Table [1](#onco13121-tbl-0001){ref-type="table"} we report the main advantages and disadvantages of the imaging modalities to assess lymph node involvement in primary breast cancer. Considering the growing importance of radiomics and radiogenomics, we provide insight into current research involving these applications in the detection of metastatic lymph nodes from breast cancer. Finally, we present our conclusions regarding for future directions that can be expected for lymphatic mapping in primary breast cancer.

###### 

Advantages and disadvantages of all modalities for lymph node imaging in primary breast cancer, with the reported range of sensibility and specificities

+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| Modality | Advantages                                                                                                            | Disadvantages                                                                                                                                                                                                     | SE    | SP       | Pooled estimates |
+:=========+:======================================================================================================================+:==================================================================================================================================================================================================================+=======+:=========+:=================+
| PE       | Accessible, primary care                                                                                              | Low sensitivity for nodal assement                                                                                                                                                                                | 30%   | 93%      | NA               |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| MG       | Inital imaging modality, ubiquitously available                                                                       | Moderate sensitivity for nodal assement                                                                                                                                                                           | 66.9% | 80.8%    | NA               |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| US       | Low cost, ubiquitously available, method of choice for nodal assesment biopsy guidance                                | Operator dependent                                                                                                                                                                                                | 87%   | 53%--97% | SE 48.8%--87.1%  |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          |                  |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          | SP 55.6%--97.3%  |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| CT       | Not recommended for primary nodal staging                                                                             | Moderate sensitivity, low specificity                                                                                                                                                                             | 72%   | 40%      | NA               |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| MRI      | Potential for LN‐specific MRI contrast agents                                                                         | Moderate sensitivity and specificity, limited ability to obtain a complete visualization of the axilla with breast MRI exam, requires dedicated axillary protocol to achieve good sensitivity and high specificty | 77%   | 90%      | SE 75%--80%      |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          |                  |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          | SP 89%--91%      |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| PET/CT   | Useful in identifying advanced axillary disease and metastatic nodal spread outside the axilla such as IMN            | Low spatial resolution and lack in anatomic details                                                                                                                                                               | 64%   | 93%      | SE 59%--69%      |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          |                  |
|          |                                                                                                                       |                                                                                                                                                                                                                   |       |          | SP 90%--95%      |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| PET/MRI  | Improves the diagnostic performance of axillary nodal staging in patients with clinically node‐positive breast cancer | Limited availablity, high costs                                                                                                                                                                                   | 77%   | 100%     | NA               |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+
| SPECT/CT | Precise anatomic localization of sentinel lymph nodes                                                                 | More expensive and not as broadly installed than planar lymphoscintigraphy                                                                                                                                        | 75%   | 90%      | NA               |
+----------+-----------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------+----------+------------------+

![](ONCO-25-e231-g008){#nlm-graphic-1}

Abbreviations: CT, computed tomography; IMN, internal mammary lymph node; LN, lymph node; MG, mammography; MRI, magnetic resonance imaging; NA, not available; PE, physical examination; PET, positron emission tomography; SE, sensitivity; SP, specificity; SPECT/CT, single‐photon emission computed tomography and computed tomography; US, ultrasoundography.

Basic Anatomy of the Axilla {#onco13121-sec-0004}
===========================

A basic knowledge of the anatomy of the axilla is important to accurately identify the location of abnormal lymph nodes using any cross‐sectional imaging techniques. As early as 1994, Giuliano et al. demonstrated that the status of the sentinel lymph node accurately reflects the status of the entire axillary basin draining a primary breast tumor [9](#onco13121-bib-0009){ref-type="ref"}. In fact, malignant cells first enter the nodes (regional spread) through an afferent lymphatic deposit in the subcapsular sinus, growing at this location and eventually replacing the local normal nodal architecture before spreading to a distant body region [10](#onco13121-bib-0010){ref-type="ref"}.

The axilla is a pyramidal space situated between the upper aspect of the thoracic wall and the medial aspect of the arm. The axilla is divided into three regions or levels by the pectoralis minor muscle (supplemental online Fig. [A](#onco13121-supitem-0002){ref-type="supplementary-material"}) [11](#onco13121-bib-0011){ref-type="ref"}:Level I: Lymph nodes infero‐lateral to the pectoralis minor (Berg\'s level 1);Level II: Lymph nodes behind the pectoralis minor (Berg\'s level 2);Level III: Lymph nodes supero‐medial to the pectoralis minor (Berg\'s level 3).

The breast lymphatics are separate from those of the underlying torso, with a subareolar plexus of lymphatics and a small number of large lymphatic vessels draining into axillary lymph nodes. Breast lymphatic drainage comprises superficial, deep, and perforating systems. The superficial system drains to the axilla, usually to level II. The deep system drains to the axilla and also anastomoses with the perforating system that drains to the internal mammary nodes. The perforating system does not connect with the superficial system. From a practical standpoint, drainage generally proceeds in order from level I to level II, to level III, and finally into the thorax [10](#onco13121-bib-0010){ref-type="ref"}.

An alternate to the axilla is the drainage to the internal mammary lymph node (IMN) chain. This runs from the anterior phrenic nodes at the diaphragm to its termination in the thoracic venous system on the right and the thoracic duct on the left, and it follows the course of the internal mammary artery and vein between the pleura/endothoracic fascia and the chest wall near the sternal margin. The IMNs are located in the first through sixth intercostal spaces, and they are largest in the first three spaces. Usually, normal internal mammary lymph nodes measure less than 6 mm (supplemental online Fig. [A](#onco13121-supitem-0002){ref-type="supplementary-material"}).

Metastases to the IMNs generally occur after a tumor has metastasized to the axilla; nodal staging is considered N3b and therefore indicates stage IIIC disease.

Past studies of extended radical mastectomy in operable breast cancer showed a prevalence of positive IMNs in 8% to 20% of patients, but the axilla also was involved in most of these patients [12](#onco13121-bib-0012){ref-type="ref"}.

Isolated metastases to the IMNs occur in 1%--5% of breast cancers and usually come from deep or medial tumors. In the absence of axillary metastases, involvement of the IMNs is considered N2 disease. There is no survival benefit to surgical treatment of internal mammary node metastases, and because of the morbidity, dissection of the nodes is not usually performed. However, the presence of IMN metastases, either in isolation or with concomitant axillary disease, does have prognostic significance and also carries a small but definite risk of local recurrence. Long‐term survival is reduced in patients with isolated internal mammary node metastases and is reduced even further in patients with both internal mammary and axillary metastases. In addition, standard tangential beam radiation therapy of the breast does not necessarily include the internal mammary nodes. Radiation treatment planning may therefore be altered if metastases of the internal mammary nodes are identified [13](#onco13121-bib-0013){ref-type="ref"}.

Histopathologic Staging of the Axilla {#onco13121-sec-0005}
=====================================

Lymph node staging for breast cancer has changed and evolved over the years with the advent of new techniques. From the mere identification of only gross deposits of cancer cells in the lymph nodes, we are now finding microscopic areas of cancer spread with histopathology.

Thus, according to the 8th edition of the AJCC Cancer Staging Manual [8](#onco13121-bib-0008){ref-type="ref"}, an isolated area of cancer spread that is smaller than 0.2 mm (or that has fewer than 200 cells) does not change the stage but is recorded with the abbreviation "i+" that reflects the presence of isolated tumor cells. If the area of cancer spread is at least 0.2 mm (or 200 cells) but not larger than 2 mm, the area is labeled as a micrometastasis and cells are counted only if there are no larger areas of cancer spread. Areas of cancer spread larger than 2 mm change the N stage. The abbreviation "mol+" is used if a molecular test, Reverse transcription polymerase chain reaction, was used to find the cancer that is not otherwise detected [14](#onco13121-bib-0014){ref-type="ref"}. It may be stressed that the use of pathologic (microscopic) confirmatory methods of nodal involvement before the removal of the primary tumor results in a clinical N category. Qualifiers for either fine‐needle aspiration cytology or core‐needle biopsy (f) and sentinel node biopsy (sn) are to be added after the N category, to reflect this degree of confidence in nodal staging and to differentiate it from staging based on palpation or imaging (e.g., cN1(f) or cN1(sn) vs. cN1). The pN category mandates the definitive removal of the primary tumor and lymph node(s) [8](#onco13121-bib-0008){ref-type="ref"}. It has to be noted that the 8th edition of the AJCC Cancer Staging Manual also allows for pN0(mol+) and pN0(mol−) categories to reflect isolated tumor cells either detected or tested but undetected by nonmorphological means [15](#onco13121-bib-0015){ref-type="ref"}. In the supplemental online [table](#onco13121-supitem-0001){ref-type="supplementary-material"}, the N‐staging from the 8th edition of TNM staging for breast cancer is summarized.

Metastatic Spread and the Need for Axillary Treatment {#onco13121-sec-0006}
=====================================================

Metastasis is a challenging clinical problem, considered the leading cause of death in breast cancer. Lymph nodes are the first regional site of metastasis and nodal disease is critical for staging and prognosis and for predicting increased mortality in many cancer types including the breast. Once a migratory cell has detached from the tumor, it may intravasate into blood vessels or lymphatics. Either route of dissemination can lead to venous circulation, as lymphatics drain into blood, most commonly through the left lymphatic duct (thoracic duct) or the right lymphatic duct, and then subsequently into the subclavian veins [16](#onco13121-bib-0016){ref-type="ref"}. However, although the potential of one detached cell to metastasize is limitless, only very few metastases eventually develop. Tumor cells forming metastases either have the autonomous characteristics while still in the primary tumor to metastasize or will acquire the needed changes induced by the environmental conditions. The potential to metastasize is not solely dependent on tumor cell traits but also modulated by the host cells, in particular platelets and bone marrow--derived cells. Tumors almost invariably invade lymph nodes in sequence, starting with the nearest (sentinel or draining) node, followed by increasingly distal ones [5](#onco13121-bib-0005){ref-type="ref"}.

Axillary Lymph Node Assessment {#onco13121-sec-0007}
==============================

Physical Examination {#onco13121-sec-0008}
--------------------

Physical examination (PE) has a low accuracy in predicting nodal involvement from breast cancer [17](#onco13121-bib-0017){ref-type="ref"}. The likelihood of axillary lymph node metastases as determined by PE only is difficult to predict and subject to a large proportion of false‐positive and false‐negative results reported sensitivity of 30%, specificity of 93%, positive predictive value (PPV) of 76%, and negative predictive value (NPV) of 67% [18](#onco13121-bib-0018){ref-type="ref"}. Furthermore, Lanng et al., in a study of 301 consecutive patients with breast cancer undergoing either axillary dissection or sentinel node procedure, demonstrated that PE of axillary lymph nodes as a criterion for offering the sentinel node procedure is of little value [19](#onco13121-bib-0019){ref-type="ref"}.

Mammography and Tomosynthesis {#onco13121-sec-0009}
-----------------------------

MG is the standard imaging modality for screening for breast disease. On the mammogram, the normal axilla is seen as an area with almost fatty density, sometimes containing small normal or reactive lymph nodes and accessory breast tissue. The sensitivity, specificity, PPV, NPV, and accuracy for mammography were 66.9%, 80.8%, 41.3%, 92.3%, and 78.4% [20](#onco13121-bib-0020){ref-type="ref"}. It is not considered reliable for the evaluation of lymph node involvement in the setting of a recent breast cancer diagnosis because of limited spatial resolution and because parts of the axillary area may not be visualized (Fig. [1](#onco13121-fig-0001){ref-type="fig"}) [21](#onco13121-bib-0021){ref-type="ref"}. Valente et al. conducted a retrospective study of 244 consecutive patients diagnosed with invasive breast carcinoma and found that MG had the highest false‐negative rate in detecting lymph node involvement in patients with breast cancer [5](#onco13121-bib-0005){ref-type="ref"}. However, MG can raise the suspicion of malignancy by identifying enlarged nodes (lymphadenopathy) in specific cases such as lymphoma or carcinoma of unknown primary.

![Female patient aged 40 years with an invasive ductal carcinoma in the left breast. **(A):** Left digital mammography, mediolateral‐oblique projection, demonstrates a high‐density lymph node in axilla and an irregular mass, spiculated, in the upper quadrants. **(B):** Ultrasonography confirmed the suspicious nature of the mass (Breast Imaging -- Reporting and Data System \[BI‐RADS\] score 5) and a single enlarged lymph node in the axilla suspicious for metastatic involvement.](ONCO-25-e231-g001){#onco13121-fig-0001}

Digital breast tomosynthesis (DBT) is also of limited value for assessing axillary nodes. The overall haziness of the axillary region on some mediolateral oblique or lateral images is a limitation from synthesizing multiple homogeneous images. The pectoral muscle has homogeneous soft‐tissue contrast without much variation; therefore, the soft‐tissue attenuation will dominate the axillary region. In addition, high‐attenuation materials in the axillary region (i.e., the shoulder) may cause more prominent artifacts compared with those at full‐field digital mammography, which are likely caused by the DBT image acquisition arc, which amplifies high‐attenuation artifacts [22](#onco13121-bib-0022){ref-type="ref"}.

Ultrasound {#onco13121-sec-0010}
----------

US is the method of choice worldwide to assess lymph node involvement in patients with known or suspected breast cancer [23](#onco13121-bib-0023){ref-type="ref"}. In the identification of nodal metastasis, morphologic criteria are more important than size criteria, which have an overall lower accuracy [7](#onco13121-bib-0007){ref-type="ref"}. A normal axillary lymph node is characterized by a reniform shape, a maximal cortical thickness of 3 mm without focal bulging, smooth margins, and, depending on size, a discernable central fatty hilum (supplemental online [Fig. B](#onco13121-supitem-0002){ref-type="supplementary-material"}) [23](#onco13121-bib-0023){ref-type="ref"}. Morphologic characteristics predictive of malignancy are cortical thickness greater than 2.5--3.0 mm, focal cortical lobulation, loss of the fatty hilum, a round shape, and abnormal cortical blood flow (nonhilar flow; Fig. [2](#onco13121-fig-0002){ref-type="fig"}) [24](#onco13121-bib-0024){ref-type="ref"}, [25](#onco13121-bib-0025){ref-type="ref"}. According to the literature, US can be highly specific if morphologic characteristics are used, with a sensitivity ranging from 26% to 76% and a specificity of 88%--98% for depicting nonpalpable metastatic lymph nodes [21](#onco13121-bib-0021){ref-type="ref"}. If the diagnosis is based on size criteria only, sensitivity and specificity are 49%--87% and 55%--97%, respectively [21](#onco13121-bib-0021){ref-type="ref"}, [26](#onco13121-bib-0026){ref-type="ref"}. In another study, Sidibé et al. [27](#onco13121-bib-0027){ref-type="ref"} confirmed that when lymph node size more than 5 mm was taken as a presumptive criterion of invasion, sensibility and specificity of ultrasonography varied from 66.1% to 87.1% and from 44.1% to 97.9%, respectively, whereas when the lymph node morphology was the mean criterion of axilla invasion, these parameters varied respectively from 40.5% to 92.3% and from 55.6% to 95.2%. The main problem we see here is that there is no guide, consensus, or Breast Imaging -- Reporting and Data System (BI‐RADS) score for lymph node assessment on US, and this is the imaging method upon which the majority of diagnoses in daily practice relies. We consider changes in morphology, cortical thickness including nonhilar vascularity, and hilar displacement.

![Sonographic morphologic characteristics that are predictors of malignancy. These include cortical thickness greater than 2.5--3.0 mm **(A, C, D)**, focal cortical lobulation **(B)**, loss of the fatty hilum **(C, D)**, a round shape **(C, D)**, and abnormal blood flow **(A, B)**.](ONCO-25-e231-g002){#onco13121-fig-0002}

US‐guided lymph node sampling, such as fine‐needle aspiration (US‐FNA) and core‐needle biopsy (US‐CNB), is indispensable for confirming the presence of a metastasis in a node suspicious on imaging (supplemental online [Fig. C](#onco13121-supitem-0002){ref-type="supplementary-material"}). US‐FNA is quick, well tolerated, and associated with minimal morbidity. US‐FNA has a moderate sensitivity, that is, 25%--87.2% (the sensitivity depends on the experience of both the operator and the pathologist). It has a specificity of 100% [1](#onco13121-bib-0001){ref-type="ref"}, [28](#onco13121-bib-0028){ref-type="ref"}. Because US‐CNB has been shown to be equally safe as US‐FNA but has a higher sensitivity, reaching 94% in some cases, several institutions have abandoned US‐FNA in favor of US‐CNB [1](#onco13121-bib-0001){ref-type="ref"}, [28](#onco13121-bib-0028){ref-type="ref"}

Elastography may improve the sensitivity and specificity of axilla sampling in breast cancer [29](#onco13121-bib-0029){ref-type="ref"}, [30](#onco13121-bib-0030){ref-type="ref"}, [31](#onco13121-bib-0031){ref-type="ref"}. Evans et al. [32](#onco13121-bib-0032){ref-type="ref"} demonstrated that using shear wave elastography (SWE), nodal involvement rates ranged from 7% for tumors with a mean stiffness less than 50 kPa to 41% for tumors with a mean stiffness greater than 150 kPa, indicating that the mean stiffness on SWE is an independent predictor of axilla metastasis.

To date, there is no consensus in marking the biopsied node with a clip [33](#onco13121-bib-0033){ref-type="ref"}. However, marking nodes with biopsy‐confirmed metastatic disease in patients undergoing neoadjuvant treatment improves the pathologic evaluation for residual nodal disease after chemotherapy [34](#onco13121-bib-0034){ref-type="ref"}.

Magnetic Resonance Imaging {#onco13121-sec-0011}
--------------------------

MRI has a minor role in the evaluation of axillary lymph nodes. The main reason is that it offers limited ability to obtain a complete visualization of the axilla when dedicated breast coils are used. Furthermore, axillary lymph nodes occasionally can be obscured by a pulsation artifact from the heart, which is worse at levels II and III.

It has been demonstrated that morphologic features on magnetic resonance (MR) images have limited accuracy for the diagnosis of axillary metastases, and as with other modalities, nodal size is not a useful parameter. MRI features suspicious for malignancy include cortical thickening, loss of fatty hilum, round shape, or a long axis to short axis ratio of less than 2 (Fig. [3](#onco13121-fig-0003){ref-type="fig"}) [12](#onco13121-bib-0012){ref-type="ref"}, [35](#onco13121-bib-0035){ref-type="ref"}, [36](#onco13121-bib-0036){ref-type="ref"}. The presence of perifocal edema, defined as the area with marked T2 prolongation in the fat surrounding a node, has been shown to have the highest positive predictive value for malignancy (100%) among predefined quantitative and qualitative descriptors [37](#onco13121-bib-0037){ref-type="ref"}."The presence of perifocal edema, defined as the area with marked T2 prolongation in the fat surrounding a node, has been shown to have the highest positive predictive value for malignancy (100%) among predefined quantitative and qualitative descriptors."

![MRI and sonographic characteristics of benign nodes. T1 fat‐saturated magnetic resonance imaging 2 minutes after administration of contrast media **(A)** in a woman aged 68 years with a suspicious mass in the median‐inner quadrant of the left breast **(B, red arrow)** showing bilateral enlarged nodes with central fatty hilum. **(C):** The targeted ultrasound demonstrated normal appearance of one of the nodes. A fine‐needle aspiration was performed with a cytologic diagnosis: polymorphous lymphoid population, negative for malignant cells.](ONCO-25-e231-g003){#onco13121-fig-0003}

After the injection of contrast medium, nodes enhance rapidly and homogeneously with a characteristic signal intensity that is higher at the periphery of a node than at its center (rim enhancement) [37](#onco13121-bib-0037){ref-type="ref"}, [38](#onco13121-bib-0038){ref-type="ref"}, [39](#onco13121-bib-0039){ref-type="ref"}, [40](#onco13121-bib-0040){ref-type="ref"}. However, radiologists cannot simply rely on the evaluation of kinetic curves (signal intensity over time), as a type III washout is not always predictive of metastasis. Dedicated protocols for axillary MRI have shown diagnostic success [41](#onco13121-bib-0041){ref-type="ref"}, [42](#onco13121-bib-0042){ref-type="ref"}. Nevertheless, although the use of dedicated axillary protocols can increase the sensitivity (84%), specificity (95%), PPV (100%), and NPV (95%) compared with standard MR examinations (sensitivity 82% and specificity 82.6%), they require additional scanning time not feasible in clinical practice [43](#onco13121-bib-0043){ref-type="ref"}. Unenhanced T1‐weighted MRI and diffusion‐weighted imaging (DWI) techniques have shown high accuracy (85% and 80%, respectively) for the detection of nodal metastases [44](#onco13121-bib-0044){ref-type="ref"}. The Dixon‐based fat‐suppressed sequence, achieving a homogeneous and excellent fat suppression, has demonstrated an overall improved image quality, especially in the axilla region, compared with spectral fat suppression techniques [45](#onco13121-bib-0045){ref-type="ref"}. Ultra‐small superparamagnetic iron oxide (USPIO)--enhanced T2‐weighted sequences have shown the most promising results, with a sensitivity of 84.7% and a mean specificity of 95% (Fig. [4](#onco13121-fig-0004){ref-type="fig"}) [46](#onco13121-bib-0046){ref-type="ref"}. These particles are composed of small size particles of an iron oxide crystalline core, coated with a low‐molecular‐weight dextran, that cross the capillary wall into the interstitial space and then drain via lymphatic vessels to lymph nodes, where they are actively taken up by the macrophages in benign nodes. When USPIO accumulates in a benign node, the particles' superparamagnetic property causes a loss in signal intensity owing to significant shortening of the T2\* relaxation time [47](#onco13121-bib-0047){ref-type="ref"}. However, although USPIO particles can serve as a contrast agent for lymph node imaging, they are not currently approved in the U.S. After intravenous USPIO administration, normal lymph nodes show an avid uptake of particles, causing a signal void because of the magnetic susceptibility effects of ferromagnetic iron oxide. Thus, metastatic lymph nodes appear brighter than normal nodes on USPIO‐enhanced images. Because of the limited spatial resolution, this technique is invaluable in detection of occult micrometastasis (defined as smaller than 1 mm), but overall its clinical use remains uncertain [46](#onco13121-bib-0046){ref-type="ref"}.

![Partial SI decrease in metastatic lymph node in a woman aged 45 years with primary stage pT2N1 tumor. Sagittal nonenhanced **(A)** and ultra‐small superparamagnetic iron oxide (USPIO)--enhanced **(B)** T2‐weighted fast spin echo magnetic resonance (MR) images (7,600/120) as well as nonenhanced **(C)** and USPIO‐enhanced **(D)** T2\*‐weighted fast field echo MR images (683/14) of left axilla show a 1.4 × 0.9 cm metastatic lymph node (large arrow) with partial signal intensity (SI) decrease after USPIO administration. Adjacent nonmetastatic node (small arrow) shows homogeneous SI decrease after USPIO administration. Primary tumor is seen. Reproduced, with permission, from Memarsadeghi et al., Axillary lymph node metastases in patients with breast carcinomas: Assessment with nonenhanced versus USPIO‐enhanced MR imaging. Radiology 2006;241:367--377 [46](#onco13121-bib-0046){ref-type="ref"}. © 2006 RSNA.](ONCO-25-e231-g004){#onco13121-fig-0004}

In our experience, during preoperative breast MRI, adding a turbo‐spin echo T2‐weighted sequence in coronal view to the classic protocol [48](#onco13121-bib-0048){ref-type="ref"}, [49](#onco13121-bib-0049){ref-type="ref"} aids in assessment of the axilla.

Computed Tomography {#onco13121-sec-0012}
-------------------

Although multidetector CT scans have a limited role in breast cancer staging, Cheung et al. [50](#onco13121-bib-0050){ref-type="ref"} reported sensitivity, specificity, PPV, NPV, and accuracy of 72%, 40%, 85.7%, 22.2%, and 66.7%, respectively, in diagnosing axillary lymph node (ALN) metastases after neoadjuvant chemotherapy. They also suggested that multidetector CT can potentially serve the role of alerting radiologists or clinicians to the possibility of false‐negative nodal micrometastases on postchemotherapy multidetector CT, especially in patients with node‐positive disease on the initial multidetector CT examination [50](#onco13121-bib-0050){ref-type="ref"}. In a recent study, Chen et. al [51](#onco13121-bib-0051){ref-type="ref"} evaluated the predictive value of preoperative multidetector‐row computed tomography (MDCT) for ALN metastasis in patients with breast cancer. In 148 cases with preoperative MDCT and ALN surgery, 61 (41.2%) cases had ALN metastasis. The cortical thickness in metastatic ALN was significantly thicker than that in nonmetastatic ALN (7.5 ± 5.0 mm vs. 2.6 ± 2.8 mm; *p* \< .001). Multilogistic regression analysis indicated that cortical thickness of \>3 mm (odds ratio \[OR\], 12.32; 95% confidence interval \[CI\], 4.50--33.75; *p* \< .001) and nonfatty hilum (OR, 5.38; 95% CI, 1.51--19.19; *p* = .009) were independent predictors for ALN metastasis. The sensitivity, specificity, and area under the curve (AUC) of MDCT for ALN metastasis prediction based on combined‐variated analysis were 85.3%, 87.4%, and 0.893 (95% CI, 0.832--0.938; *p* \< .001), respectively. Chen et al. concluded that cortical thickness (\>3 mm) and nonfatty hilum of MDCT were independent predictors for ALN metastasis. MDCT can be a potent imaging tool for predicting ALN metastasis in breast cancer [51](#onco13121-bib-0051){ref-type="ref"}.

In cases when traditional techniques fail in identifying lymph nodes within the axilla, CT guidance for localization in the axilla is an option if the clip is not visible on US or mammogram [52](#onco13121-bib-0052){ref-type="ref"}. In the case that the axillary clip cannot be identified on US and the location is very high up in the axilla, a noncontrast CT limited to the axillary region can help to recognize the previously biopsied lymph node. This is especially true in patients undergoing neoadjuvant chemotherapy, in whom the localization of the clip within the node can be difficult even in MRI.

Kim et al. [53](#onco13121-bib-0053){ref-type="ref"} studied breast cancer to assess the reliability of sentinel lymph node biopsy (SLNB) for axillary restaging after NAC to determine the possibility of image‐guided marker‐clip placement in axillary lymph nodes. In 20 patients they placed a marker‐clip at a clinically positive axillary lymph node under US guidance before initiation of NAC. Preoperative localization of marker‐clipped lymph nodes was performed, and the localized lymph nodes were removed by SLNB. Then they compared the postoperative results of the marker‐clipped lymph nodes, sentinel nodes, and axillary lymph nodes. A total of 24 marker clips were inserted, and 23 marker‐clipped lymph nodes were successfully retrieved during surgery (identification rate, 23/24, 95.8%). In the 11 patients with pathologically confirmed metastatic marker‐clipped lymph nodes, four became negative after NAC, and seven maintained metastatic residues on the marker‐clipped lymph nodes. Three of the seven patients had metastatic residues on the axillary lymph nodes, and two of the three patients also had negative sentinel nodes. Marker‐clipped nodes accurately predicted the axillary nodal status in these two patients compared with sentinel nodes alone. Kim et al. concluded that image‐guided marker‐clip placement on positive axillary lymph nodes before NAC and removal with SLNB are technically feasible. This technique can improve the accuracy of the residual disease evaluation on the axilla, especially in patients with negative SLNB results, and can identify candidates for limited axillary surgery after NAC [53](#onco13121-bib-0053){ref-type="ref"}.

Positron Emission Tomography/Computerized Tomography {#onco13121-sec-0013}
----------------------------------------------------

Positron emission tomography (PET) using 18F‐fluorodeoxyglucose (FDG) enables the identification of the increased glucose metabolism that is typical of malignant tumors [54](#onco13121-bib-0054){ref-type="ref"}. Low spatial resolution and lack of anatomic details are the main limitations of PET, rendering it an insufficient tool for detecting metastases, with sensitivity from 25% to 84%. On the other hand, PET devices combined with CT, that is, PET/CT scanners, are useful in identifying advanced axillary disease and metastatic nodal spread outside the axilla, especially in the internal mammary chain, with high sensitivity (80%--94%) and specificity (86%--90%) [55](#onco13121-bib-0055){ref-type="ref"}. In patients with breast cancer who will undergo neoadjuvant chemotherapy, the use of PET/CT as a staging procedure prevents unnecessary sentinel lymph node biopsies, enables axillary response monitoring during or after neoadjuvant chemotherapy, and guides treatment planning by detecting occult nodal and distant metastases (Fig. [5](#onco13121-fig-0005){ref-type="fig"}) [56](#onco13121-bib-0056){ref-type="ref"}. Nevertheless, PET/CT is not yet sufficiently sensitive for the detection of primary breast cancer or for the evaluation of axillary lymph nodes in early‐stage breast cancer (stage I and II). PET/CT has a low accuracy for micrometastases, with a drop in sensitivity to 33% [57](#onco13121-bib-0057){ref-type="ref"}. Thus, it cannot be used as a standard tool for axillary staging of operable breast cancer.

![A woman aged 45 years with invasive ductal cancer of the right breast. Computed tomography (CT) of the whole body. Axial **(A)** and coronal **(D)** views show enlarged node in the right axilla **(A, arrow; C)** associated with an irregular mass within the right breast **(A, circle)**. Whole body positron emission tomography (PET) examination. Axial **(B)** and coronal **(E)** views demonstrate high fluorodeoxyglucose uptake for both the mass and the enlarged node in the axilla that is also confirmed by hybrid imaging PET/CT **(C, F)**.](ONCO-25-e231-g005){#onco13121-fig-0005}

Other high‐resolution breast‐specific devices have been introduced as an alternative to MRI, especially when a contraindication is found, such as positron emission mammography (PEM). By enabling the coregistration of mammography and emission FDG images of the breast, PEM is a valid method for local staging of early breast cancer. However, although the data are limited concerning its application, preliminary results have shown low accuracy of this modality for axillary staging [58](#onco13121-bib-0058){ref-type="ref"}.

Positron Emission Tomography/Magnetic Resonance Imaging {#onco13121-sec-0014}
-------------------------------------------------------

PET/MRI has been designed to combine the specificity obtained from functional imaging, that is, PET, with the superior sensitivity obtained from MRI to provide relevant information and achieve a higher diagnostic accuracy in a single session [59](#onco13121-bib-0059){ref-type="ref"}. Van Nijnatten et al. [60](#onco13121-bib-0060){ref-type="ref"} investigated the value of dedicated axillary 18F‐FDG PET/MRI in comparison with standard imaging modalities for axillary nodal staging in patients with clinical suspicion of lymph node metastasis. Twelve patients underwent axillary US and dedicated axillary hybrid 18F‐FDG PET/MRI. Nine of the 12 patients also underwent whole body PET/CT. The authors measured the maximum standardized uptake values (SUVmax) for the primary breast tumor and the most FDG‐avid axillary lymph node. They found no significant difference in mean SUVmax for the primary tumor and the most FDG‐avid axillary lymph node when comparing dedicated axillary PET/MRI and PET/CT. Dedicated axillary hybrid PET/MRI changed nodal staging from conventional imaging as follows: 40% compared with US, 75% compared with T2‐weighted MRI, 40% compared with contrast‐enhanced MRI, and 22% compared with PET/CT.

For N‐staging, PET/MRI showed similar results of diagnostic accuracy with PET/CT (86% vs. 88%) and tended to be higher than MRI (80%). Another study showed that PET/MRI provided lower sensitivity for primary tumor than MRI (77% vs. 100%) but higher specificity (100% vs. 67%). For N‐staging, the difference between PET/MRI and MRI was not statistically significant [61](#onco13121-bib-0061){ref-type="ref"}, [62](#onco13121-bib-0062){ref-type="ref"}, [63](#onco13121-bib-0063){ref-type="ref"}.

Initial data indicate dedicated axillary 18F‐FDG hybrid PET/MRI of the diagnostic workup has the potential to improve the diagnostic performance of axillary nodal staging in patients with clinically node‐positive breast cancer, but further studies will be needed to corroborate and expand the current evidence.

Single‐Photon Emission Computed Tomography/Computed Tomography {#onco13121-sec-0015}
--------------------------------------------------------------

The recent introduction of integrated single‐photon emission computed tomography and computed tomography (SPECT/CT) scanners was mainly due to the need for an imaging method that can offer more precise anatomic localization of sentinel lymph nodes. These systems have yielded broad consensus, especially in the evaluation of sentinel nodes in patients with complex lymphatic drainage, extra‐axillary metastatic spread, or an increased body mass index [64](#onco13121-bib-0064){ref-type="ref"}, and provide information on the drainage pattern when conventional imaging is inconclusive (nonvisualization or unclear location of the nodes). By enhancing the topographic orientation, SPECT/CT is thus more valuable than planar lymphoscintigraphy for sentinel lymph node detection; it has shown higher accuracy in the case of enlarged solid lymph nodes or normal‐sized nodes with intense tracer uptake or uptake as high as that in muscles (sensitivity 75%, specificity 90%) (Fig. [6](#onco13121-fig-0006){ref-type="fig"}) [65](#onco13121-bib-0065){ref-type="ref"}."By enhancing the topographic orientation, SPECT/CT is thus more valuable than planar lymphoscintigraphy for sentinel lymph node detection; it has shown higher accuracy in the case of enlarged solid lymph nodes or normal‐sized nodes with intense tracer uptake or uptake as high as that in muscles (sensitivity 75%, specificity 90%)."

![Single‐photon emission computed tomography (SPECT) of the breast. A patient aged 50 years after left lumpectomy with left axillary nodal dissection with recurrent left breast cancer undergoing left breast lymphoscintigraphy. Lymphoscintigraphy shows extensive heterogeneous tracer accumulation throughout the skin of the left breast, including multiple serpiginous trails of activity as well as irregular accumulations **(A)**. Additionally, isolated foci are seen in the right axillary region and lower left neck. SPECT and computed tomography localize these two foci to the right axilla **(B)** and left supraclavicular region **(C)**. Additionally, a left internal mammary node was visualized **(D)**.](ONCO-25-e231-g006){#onco13121-fig-0006}

A Perspective of the Future: Radiomics and Radiogenomics Era {#onco13121-sec-0016}
------------------------------------------------------------

Radiomics, a new and rapidly evolving field of research, converts medical images into quantifiable data such as phenotypic characteristics of the entire tumor [66](#onco13121-bib-0066){ref-type="ref"}, [67](#onco13121-bib-0067){ref-type="ref"}. To date, radiomics research in breast imaging has mainly focused on dynamic contrast‐enhanced magnetic resonance imaging [20](#onco13121-bib-0020){ref-type="ref"}, [68](#onco13121-bib-0068){ref-type="ref"}, [69](#onco13121-bib-0069){ref-type="ref"}, [70](#onco13121-bib-0070){ref-type="ref"}, [71](#onco13121-bib-0071){ref-type="ref"} and the assessment of the primary tumor for the differentiation of molecular breast cancer subtypes, correlation with recurrences scores, or correlation with individual gene signatures [72](#onco13121-bib-0072){ref-type="ref"}, [73](#onco13121-bib-0073){ref-type="ref"}, [74](#onco13121-bib-0074){ref-type="ref"}. Recently, radiomics and radiogenomics analyses have also focused on nodal assessment with encouraging results. In a recently published study in 2018, Dong et al. reported the potential of radiomics analysis extrapolated from T2‐weighted fat suppression (T2w‐FS) and DWI for the preoperative prediction of sentinel lymph nodes [75](#onco13121-bib-0075){ref-type="ref"}. The authors found AUCs from 0.770 to 0.863 for both the T2w‐FS model and DWI models and concluded that full utilization of breast cancer--specific textural features extracted from anatomical and functional MR images improves the performance of radiomics in predicting sentinel lymph node metastasis, providing a noninvasive approach in clinical practice.

Using a different approach, Han et al. [76](#onco13121-bib-0076){ref-type="ref"} developed a radiomic nomogram for preoperative prediction of axillary lymph node metastasis in patients with breast cancer. Based on a radiomic signature and clinical features, a nomogram was developed that showed excellent predictive ability for lymph node metastasis (AUC 0.84 and 0.87 in training and validation sets, respectively). Another radiomic signature was constructed to distinguish the number of metastatic lymph nodes (fewer than two positive nodes vs. more than two positive nodes), which also showed moderate performance (AUC 0.79). The authors concluded that both nomogram and radiomic signatures can be used as tools to assist clinicians in assessing lymph node metastasis in patients with breast cancer (Fig. [7](#onco13121-fig-0007){ref-type="fig"}).

![Radiomics workflow. Reprinted by permission from Springer Nature, from Han et al., Radiomic nomogram for prediction of axillary lymph node metastasis in breast cancer. European Radiology 2019;7:3820--3829 [76](#onco13121-bib-0076){ref-type="ref"}. © 2019 European Society of Radiology.\
Abbreviations: LN, lymph node; ROI, region of interest.](ONCO-25-e231-g007){#onco13121-fig-0007}

Multiparametric MRI is not the only method in which the potential of radiomics in predicting node involvement has been tested. Yang et al. [77](#onco13121-bib-0077){ref-type="ref"} developed a mammography‐based radiomics nomogram for the preoperative prediction of axillary lymph node metastasis in 147 patients with breast cancer. The authors extracted radiomics features from each patient\'s mammography images and incorporated the radiomics signature with the clinicopathologic risk factors into a nomogram. Suo et al. [78](#onco13121-bib-0078){ref-type="ref"} explored the diagnostic value of quantitative radiomics features from elastography and B‐mode for axillary lymph node metastasis in 158 patients with breast cancer. The authors extracted a total of 428 features, consisting of morphologic features from B‐mode and intensity features and gray‐level co‐occurrence matrix features from the dual modalities; they found a sensitivity, specificity, and accuracy of 86.96%, 85.51%, and 86.34%, respectively.

The presented results demonstrate that the fields of radiomics and radiogenomics need further development but that they have already shown to open new frontiers for the assessment of lymph nodes in patients with breast cancer.

Conclusion {#onco13121-sec-0017}
==========

US of the axilla is the method of choice for the assessment of metastatic involvement of lymph nodes in all patients with highly suspicious lesions or with a known breast cancer. It must be noted that the accuracy of US is moderate but also that its accuracy can be improved with image‐guided percutaneous sampling. In the case of inconclusive conventional images (nonvisualization or unclear location of the nodes), SPECT/CT may add valuable information and is routinely used for surgical planning. To improve pretreatment assessment of lymph nodes in patients with breast cancer, new avenues such as functional imaging with PET/CT, PET/MRI, the use of specific contrast agents, and radiomics and radiogenomics have been explored with encouraging results. However, further studies will be necessary confirm their clinical value.
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